» Articles » PMID: 1648447

Induction of Bcl-2 Expression by Epstein-Barr Virus Latent Membrane Protein 1 Protects Infected B Cells from Programmed Cell Death

Overview
Journal Cell
Publisher Cell Press
Specialty Cell Biology
Date 1991 Jun 28
PMID 1648447
Citations 330
Authors
Affiliations
Soon will be listed here.
Abstract

Epstein-Barr virus (EBV) not only induces growth transformation in human B lymphocytes, but has more recently been shown to enhance B cell survival under suboptimal conditions where growth is inhibited; both effects are mediated through the coordinate action of eight virus-coded latent proteins. The effect upon cell survival is best recognized in EBV-positive Burkitt's lymphoma cell lines where activation of full virus latent gene expression protects the cells from programmed cell death (apoptosis). Here we show by DNA transfection into human B cells that protection from apoptosis is conferred through expression of a single EBV latent protein, the latent membrane protein LMP 1. Furthermore, we demonstrate that LMP 1 mediates this effect by up-regulating expression of the cellular oncogene bcl-2. The interplay between EBV infection and expression of this cellular oncogene has important implications for virus persistence and for the pathogenesis of virus-associated malignant disease.

Citing Articles

Combination of bortezomib and venetoclax targets the pro-survival function of LMP-1 and EBNA-3C of Epstein-Barr virus in spontaneous lymphoblastoid cell lines.

Tam K, Xie J, Au-Yeung R, Chiang A PLoS Pathog. 2024; 20(9):e1012250.

PMID: 39325843 PMC: 11481030. DOI: 10.1371/journal.ppat.1012250.


Epstein-Barr virus lytic gene BNRF1 promotes B-cell lymphomagenesis via IFI27 upregulation.

Sagou K, Sato Y, Okuno Y, Watanabe T, Inagaki T, Motooka Y PLoS Pathog. 2024; 20(2):e1011954.

PMID: 38300891 PMC: 10833513. DOI: 10.1371/journal.ppat.1011954.


Recent Advances in Assessing the Clinical Implications of Epstein-Barr Virus Infection and Their Application to the Diagnosis and Treatment of Nasopharyngeal Carcinoma.

Yoshizaki T, Kondo S, Dochi H, Kobayashi E, Mizokami H, Komura S Microorganisms. 2024; 12(1).

PMID: 38276183 PMC: 10820804. DOI: 10.3390/microorganisms12010014.


Pre-Emptive Use of Rituximab in Epstein-Barr Virus Reactivation: Incidence, Predictive Factors, Monitoring, and Outcomes.

Papalexandri A, Gavriilaki E, Vardi A, Kotsiou N, Demosthenous C, Constantinou N Int J Mol Sci. 2023; 24(22).

PMID: 38003218 PMC: 10671524. DOI: 10.3390/ijms242216029.


Shaping the host cell environment with viral noncoding RNAs.

Gorbea C, Elhakiem A, Cazalla D Semin Cell Dev Biol. 2022; 146:20-30.

PMID: 36581481 PMC: 10101873. DOI: 10.1016/j.semcdb.2022.12.008.